Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 4/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 10/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962052 | 0.81 | BACE1 (0.41) | BACE1ALDH1A1HPGDCYP2C19KDM4E | |
| SCHEMBL21962185 | 0.70 | KDM4E (0.51) | BACE1ALDH1A1HPGDCYP2C19KDM4E | |
| SCHEMBL22014641 | 0.68 | KDM4E (0.45) | BACE1ALDH1A1HPGDCYP2C19KDM4E | |
| SCHEMBL21962149 | 0.67 | KDM4E (0.47) | BACE1ALDH1A1HPGDCYP2C19KDM4E | |
| SCHEMBL21962071 | 0.67 | ALDH1A1 (0.40) | ALDH1A1HPGDCYP2C19KDM4EPPARG | |
| SCHEMBL20699039 | 0.66 | NLRP3 (0.35) | — | |
| SCHEMBL22014405 | 0.64 | SMYD3 (0.32) | — | |
| SCHEMBL20698743 | 0.64 | NLRP3 (0.34) | — | |
| SCHEMBL28856911 | 0.59 | CYTH2 (0.51) | ALDH1A1PPARG | |
| SCHEMBL21962308 | 0.58 | KDM4E (0.53) | BACE1ALDH1A1HPGDCYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| EP-3880658-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | BACE1 1146/4885ALDH1A1 2123/4885HPGD 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.